Expression of CTGF and TNFa in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine or interferon-γ-1b

Pneumon

Volumn 24, Issue 2, 2011, Pages 149-156

  Xifteri, Areti ^a   Drakopanagiotakis, Fotis ^a   Tzouvelekis, Argyris ^c   Tsiambas, Evangelos ^b   Karameris, Andreas ^b   Tsakanika, Katerina ^a   Polychronopoulos, Vlassis ^a   Bouros, Demosthenes ^c  

^a Sismanoglio General District Hospital   (Greece)

^b NIMTS HOSPITAL   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Alveolar macrophages; Azathioprine; Bronchoalveolar lavage; CTGF; Idiopathic pulmonary fibrosis; Interferon 1b; TNF

Indexed keywords

AZATHIOPRINE; CONNECTIVE TISSUE GROWTH FACTOR; GAMMA1B INTERFERON; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS MACROPHAGE; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; MALE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 79960293565     PISSN: 1105848X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS.JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183:788-824.
2. Bouros D. Combined pulmonary fibrosis and emphysema syndrome. Pneumon 2009; 22:128-130.
3. American Thoracic Society. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165:277-304.
4. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345:517-525.
5. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
6. Antoniou KM, Alexandrakis MG, Siafakas NM, Bouros D. Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:91-104.
7. Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor-a suppresses the induction of connective tissue growth factor by transforming growth factor-b in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-16225.
8. Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001;17:1220-1227.
9. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39-49.
10. Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 2005;11:3943-3971.
11. Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997;158:954-959.
12. Fujita M, Shannon JM, Morikawa O, Gauldie J, Hara N, Mason RJ. Over expression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am J Respir Cell Mol Biol 2003;29:669-676.
13. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-296.
14. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006;28:496-504.
15. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-133.
16. Malagari K, Siafakas N, Economidou F, et al. Clinical, radiological and molecular effects in three patients with idiopathic pulmonary fibrosis after long-term treatment with interferon gamma-1b. Pneumon 2009;22:162-168.
17. Bouros D. The new ATS/ERS/JRS IPF Guidelines. Pneumon 2008; 21:117-118.
18. Bouros D. Interferon gamma for idiopathic pulmonary fibrosis. Lancet 2009;374:180-182.
19. Karagiannidis N, Tsakanika K, Drakopanagiotakis F, et al. Syndromes, diseases and the challenge of definitions in intensive care medicine: the case of acute respiratory distress syndrome. Pneumon 2009;22:247-253.
20. Keane MP. The role of chemokines and cytokines in lung fibrosis, Eur Respir Rev 2008;17:109,151-156.
21. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-tomacrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006;177:7303-7311.
22. Tzouvelekis A, Bouros E, Bouros D. The Immunology of pulmonary fibrosis: The role of Th1/Th2/Th17/Treg cells. Pneumon 2010;23:17-20.
23. Kotsianidis I, Bouros D, Nakou E, Tzouvelekis A. Impaired T cell regulation in interstitial lung disease: a new culprit for an old case? Pneumon 2007;20:327-329.
24. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-346
25. Shearer JD, Richards JR, Mills CD, Caldwell MD. Differential regulation of macrophage arginine metabolism:a proposed role in wound healing. Am J Physiol 1997;272:E181-E190.
26. Robert M. Strieter What Differentiates Normal Lung Repair and Fibrosis? Inflammation, Resolution of Repair, and Fibrosis Proc Am Thorac Soc 2008;5:305-310.
27. Technical recommendations and guidelines for bronchoalveolar lavage (BAL): Report of the European Society of Pneumology Task Group. Eur Respir J 1989;2:561-585.
28. Clinical guidelines and indications for bronchoalveolar lavage (BAL): Report of the European Society of Pneumology Task Group on BAL. Eur Respir J 1990;3:937-976.
29. Tzortzaki EG, Antoniou KM, Zervou MI, et al. Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med. 2007; 101:1821-1929.
30. Martinez JA, King TE Jr, Brown K, et al. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol. 1997;273:L676-L683.
31. Homolka J, Ziegenhagen MW, Gaede KI, Entzian P, Zissel G, Müller-Quernheim J. Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration. 2003; 70:262-269.
32. Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology. 1993; 22:343-347.
33. King TE Jr, Albera C, Bradford WZ, et al; INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-228.
34. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26:693-702.
35. Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
36. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis, Lancet 2011;377:1727-1729.
37. Antoniou KM, Ferdoutsis E, Bouros D. Interferons and their application in the diseases of the lung. Chest 2003;123:209-216.